Structure Therapeutics INC Form 4 insider transactions

John Joseph Berrios, Chief Commercial Officer of Structure Therapeutics Inc., reported multiple transactions in common stock on August 6, 2026.

Xichen Lin, CHIEF SCIENTIFIC OFFICER of Structure Therapeutics Inc., sold 3,939 shares of common stock on August 4, 2026.

Fmr Llc reported changes in beneficial ownership of Structure Therapeutics Inc. common stock on July 22, 2026.

Xichen Lin, CHIEF SCIENTIFIC OFFICER of Structure Therapeutics Inc., sold 7,878 shares of common stock on July 14, 2026.

Structure Therapeutics Chief Scientific Officer Lin Xichen reported a transaction involving the sale of American Depositary Shares acquired through an option exercise, as part of a Rule 10b5-1 trading plan.

Angus C. Russell, a Director at Structure Therapeutics Inc., has acquired stock options, with vesting scheduled over the next year.

Ted W. Love, a Director at Structure Therapeutics Inc., acquired stock options on June 17, 2026, as detailed in a Form 4 filing.

Joanne Waldstreicher, a Director at Structure Therapeutics Inc., has acquired 39,453 ordinary shares through the exercise of stock options.

Eric Dobmeier, a Director at Structure Therapeutics Inc., has acquired 39,453 ordinary shares through the exercise of stock options.

Sharon Tetlow, a Director at Structure Therapeutics Inc., has acquired 39,453 ordinary shares through the exercise of stock options.

Daniel G. Welch, a Director at Structure Therapeutics Inc., has acquired 39,453 ordinary shares through the exercise of stock options.

Matthew Lang, COO & GC of Structure Therapeutics Inc., received a grant of restricted stock units and a stock option on April 15, 2026.

FMR LLC, a 10% owner of Structure Therapeutics, disclosed the sale of American Depositary Shares on April 14, 2026.

Structure Therapeutics Inc. granted Restricted Stock Units and employee stock options to its Chief Development Officer, Ashley Hall, as part of her compensation package.

Structure Therapeutics' Chief Medical Officer, Blas Coll Crespo, received significant equity grants including restricted stock units and stock options.

Structure Therapeutics Inc.'s Chief Technology Officer, Ma Yingli, was granted 32,526 Restricted Stock Units and 40,278 employee stock options on March 19, 2026.

Structure Therapeutics' Chief Scientific Officer, Xichen Lin, received significant equity awards, including restricted stock units and stock options, on March 19, 2026.

Structure Therapeutics Inc.'s Chief Financial Officer, Jun Yoon, was granted 104,085 restricted stock units and options to purchase 128,892 ordinary shares.

Structure Therapeutics Inc. CEO Raymond C. Stevens received grants of restricted stock units and employee stock options, aligning his incentives with long-term company performance.

Structure Therapeutics' Chief Medical Officer, Blas Coll Crespo, disposed of 11,826 ordinary shares to cover tax obligations related to a restricted share unit award vesting.

Structure Therapeutics' Chief Technology Officer, Ma Yingli, reported a disposition of 11,313 ordinary shares for tax withholding purposes related to a restricted share unit award.

Structure Therapeutics' Chief Scientific Officer, Xichen Lin, disposed of 18,735 ordinary shares at $20.99 each to cover tax obligations from a restricted share unit award vesting.

Structure Therapeutics' CFO, Jun Yoon, disposed of 22,305 ordinary shares to cover tax obligations related to a restricted share unit award vesting.

Ashley Hall, Chief Development Officer of Structure Therapeutics, reported routine share transactions including a tax-related sale and Employee Share Purchase Plan acquisitions.

Structure Therapeutics CEO Raymond C. Stevens reported both the acquisition of American Depositary Shares through an employee plan and the disposition of ordinary shares for tax obligations.

FMR LLC, a significant shareholder, reported multiple sales of American Depositary Shares in Structure Therapeutics Inc. on January 15, 2026, reducing its indirect beneficial ownership.

FMR LLC, a significant shareholder and affiliate of Structure Therapeutics Inc., reported multiple sales of American Depositary Shares on December 8, 2025.

Structure Therapeutics' Chief Development Officer, Ashley Hall, disposed of 6,021 ordinary shares to cover tax liabilities from a restricted share unit award vesting.

Structure Therapeutics' Chief Medical Officer, Blas Coll Crespo, disposed of 8,106 ordinary shares to cover tax obligations related to a restricted share unit award vesting.

Structure Therapeutics' Chief Technology Officer had 4,470 shares withheld to cover income tax obligations related to a restricted share unit award.